目的 探討前列舒通膠囊聯(lián)合愛普列特片治療良性前列腺增生的臨床療效。方法 選取2015年7月—2016年7月遵義醫(yī)學(xué)院第五附屬（珠海）醫(yī)院進(jìn)行治療的90例良性前列腺增生患者，根據(jù)治療方案的差別分為對照組（45例）和治療組（45例）。對照組患者口服愛普列特片，5 mg/次，2次/d。治療組在對照組的基礎(chǔ)上口服前列舒通膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療12周。治療后，觀察兩組患者臨床療效，同時比較治療前后兩組患者IPSS和QOL評分、觀察指標(biāo)及不良反應(yīng)情況。結(jié)果 治療后，對照組和治療組的總有效率分別為80.00%、95.56%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組IPSS和QOL評分均明顯減低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P< 0.05）；且治療組患者IPSS和QOL評分降低更明顯，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組患者前列腺體積、殘余尿量均顯著減小，而最大尿流率明顯增加，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P< 0.05）；且治療組上述指標(biāo)顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。兩組不良反應(yīng)發(fā)生情況比較差異無統(tǒng)計學(xué)意義。結(jié)論 前列舒通膠囊聯(lián)合愛普列特片治療良性前列腺增生效果顯著，可明顯改善患者臨床癥狀及生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Qianlie Shutong Capsules combined with Epristeride Tablets in treatment of benign prostatic hyperplasia. Methods Patients (90 cases) with benign prostatic hyperplasia in the Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University from July 2015 to July 2016 were randomly divided into control (45 cases) and treatment groups (45 cases) based on different treatments. Patients in the control group were po administered with Epristeride Tablets, 5 mg/time, twice daily. Patients in the treatment group were po administered with Qianlie Shutong Capsules on the basis of the control group, three grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated; IPSS and QOL scores, observational indexes, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, IPSS and QOL scores in two groups significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, prostate volume and residual urine volume was significantly decreased, while the maximum urinary flow rate was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). There were no adverse reactions in two groups.Conclusion Qianlie Shutong Capsules combined with Epristeride Tablets has significant therapeutic effect in treatment of benign prostatic hyperplasia, can significantly improve the clinical symptoms and quality of life, which has a certain clinical application value of clinical application.